Drug News

Global Pharmaceutical Contract Manufacturing Market Report 2023-2030

The “Global Pharmaceutical Contract Manufacturing Market – Forecast to 2030” report, recently added to ResearchAndMarkets’s offerings, provides a comprehensive analysis of the pharmaceutical contract manufacturing (PCM) global market.

The market is projected to experience a mid single-digit Compound Annual Growth Rate (CAGR) from 2023 to 2030, ultimately reaching an estimated value of $100,102.8 million by 2030.

Market Growth Factors

1.        Rapid Industry Expansion: The global pharmaceutical market is witnessing rapid growth, driven by factors such as increased research and development, manufacturing advancements, and significant developments in formulation techniques.

2.        Key Market Drivers:

•          Rising global population.

•          Increased prevalence of chronic diseases (e.g., infectious diseases, oncology, cardiovascular disorders).

•          Substantial growth in healthcare spending.

•          Surge in collaborations, mergers, and acquisitions within the pharmaceutical industry.

3.        Role of Contract Manufacturing Organizations (CMOs):

•          Pharmaceutical companies are turning to CMOs to meet growing demand and address challenges.

•          CMOs provide advanced facilities, technologies, and high containment capabilities for manufacturing.

•          Outsourcing to CMOs allows pharmaceutical companies to focus on core strengths and benefit from specialized manufacturing expertise.

4.        Market Segmentation:

•          Contract pharmaceutical manufacturing services primarily focus on Active Pharmaceutical Ingredients (API) and Finished Dosage Formulations (FDF).

Opportunities and Challenges:

1.        Opportunities:

•          Increased outsourcing.

•          High adoption of small molecule drugs across therapeutic areas.

•          Patent expiration and the use of the 505(b)(2) pathway for small molecule drugs.

•          Advanced technologies in API and FDF manufacturing.

•          Rising R&D expenditures.

•          Capacity and capability expansion in advanced Highly Potent APIs and Complex Molecules platforms.

2.        Challenges:

•          Pharmaceutical product contamination (API and FDF).

•          Pricing pressure.

•          Need for highly skilled technicians.

•          Increasing adoption of biologics in disease management.

•          Stringent regulatory policies.

•          Environmental concerns.

Regional Insights:

1.        North America:

•          Largest revenue contributor in 2023.

•          Expected mid-single-digit CAGR growth from 2023 to 2030.

•          Growth drivers include increasing pharma R&D expenditure, new drug developments, approvals of generics, and government support.

2.        Asia-Pacific:

•          Anticipated high single-digit CAGR growth from 2023 to 2030.

•          Key drivers include increasing production of generic pharmaceuticals, extensive manufacturing facilities, and government investments.

•          India plays a significant role with over 3,000 pharmaceutical companies and more than 10,500 manufacturing facilities.

Major Companies

Overview, Financials, Product Portfolio, Key Developments, Business Strategy, SWOT Analysis:

•          Abbvie Inc.

•          Asymchem Laboratories (Tianjin) Co. Ltd

•          Cambrex Corporation

•          Curia

•          Delpharm – Delriv

•          Lonza Group Ltd

•          Porton Pharma Solutions Ltd

•          Recipharm Ab

•          Thermo Fisher Scientific Inc

•          Wuxi Apptec Co. Ltd.

Key Elements of Major Companies Analysis

•          Financial overview.

•          Product portfolio analysis.

•          Key developments in the industry.

•          Business strategy evaluation.

•          SWOT analysis.

The “Global Pharmaceutical Contract Manufacturing Market – Forecast to 2030” report offers a thorough examination of the pharmaceutical contract manufacturing landscape, providing valuable insights for industry stakeholders, investors, and decision-makers. The analysis encompasses market growth factors, opportunities, challenges, regional dynamics, and detailed profiles of major market players.


Joan David-Leonhard

Joan David Leonhard is a recent Pharm.D graduate with a strong passion for the pharmaceutical industry and a particular interest in pharmaceutical media and communication. Her brief internship experience includes roles in pharmacy where she built strong patient-pharmacist relationships and a pharmaceutical media internship where she actively contributed to drug information articles, blog posts, social media engagement, and various media projects.
Back to top button

Adblock Detected

Please consider supporting us by disabling your ad blocker